Details of Drug-Drug Interaction
| Drug General Information (ID: DDIYS16AP2) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Piroxicam | Drug Info | Diclofenac (topical) | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Analgesics | Nsaids/Analgesics | |||||||
| Structure | |||||||||
| Mechanism of Piroxicam-Diclofenac (topical) Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of hepatotoxicity Click to Show/Hide Mechanism Graph | |||||||||
![]() |
|||||||||
| Drug Name | Piroxicam | Diclofenac (topical) | |||||||
| Mechanism | Hepatotoxicity | Hepatotoxicity | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Hepatotoxicity | ||||||||
| Factor Description | Combination of drugs that can induce hepatotoxicity may increase the risk of liver injury. Symptoms vary depending on the level of exposure and the total extent of liver damage, and may cause few symptoms if the damage is mild, and eventually lead to liver failure in patients with severe damage. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Patients treated with topical preparations of nonsteroidal anti-inflammatory drugs should avoid or limit the use of systemic nonsteroidal anti-inflammatory drugs. Although systemic exposure is generally low following topical administration, absorption may be increased with frequent applications use of large quantities or over large areas of skin use on compromised or diseased skin or open wounds and use of occlusive dressings or heating pads over application areas. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Solaraze (diclofenac topical). Doak Dermatologics Division, Fairfield, NJ. | ||||||||||||||||||

